A study testing whether a GLP-1 medicine from Veru, semaglutide, can help with weight.

Who can join

Adults 65 to 100, have obesity or are overweight, BMI 35+.

What you take

semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.

How long it lasts

The full study runs about 1.8 years; your own time in it is usually shorter.

What you get

The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

What this study is for

Full study title: Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist.

Primary condition: Obesity & Overweight. Also studied in: Mobility Disability, HOMA-IR.

Who can join, in detail

Key inclusion criteria

• Subjects accepted for this study must:
• Provide informed consent from the subject or the subject's legally authorized representative
• Be able to communicate effectively with the study personnel
• Be >=65 years of age at the time of screening
• For Female Subjects Menopausal status

Key exclusion criteria

• Known hypersensitivity or allergy to enobosarm or a GLP-1 receptor agonist
• Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 as measured using the chronic kidney disease-epidemiology collaboration (CKD-EPI) calculation (patients with mild and moderate renal failure are not excluded from participation in this study)
• Treatment with any investigational product within < 5 half-lives for each individual investigational product OR within 30 days prior to randomization
• Major surgery (the surgery poses a significant risk to patients life and requires general anesthesia) within 30 days prior to randomization
• Planned major surgery during the course of the study or any cosmetic surgery potentially impacting body composition, e.g., liposuction, implants, or removal of any current implants

Where this study is enrolling

This trial has 10 US sites across 6 states. Contact the site coordinator directly to start the screening process.

Timeline

Started enrolling: 2026-03-26. Expected completion: 2027-12. Last updated on ClinicalTrials.gov: 2026-04-22.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Other GLP-1 clinical trials

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact